Clinical trials: Neoplasm Circulating Cells
Healthy Volunteers, Breast Cancer, Metastatic
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
The purpose of this clinical study is to demonstrate that the Parsortix™ PC1 system enables the capture and harvest of circulating tumor cells (CTCs) from the peripheral blood of patients with metastatic breast cancer (MBC) and…
- Trial name
- HOMING (NCT03427450)
- Testing
- Blood draw
- Where
- 4 sites in United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- Angle plc
Objective Responsive Rate (ORR)
Dynamic Changes in Circulating Tumour Cells Protein Expression
This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at…
- Trial name
- Liquid-DRER2 (NCT06314997)
- Testing
- panitumumab (EGFR inhibitors)
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Matteo's Friends
Chaperonin-Containing TCP-1, Circulating Tumor Cells
Liquid Biopsy Collection Study
The purpose of this study is to develop a liquid biopsy approach for detection of circulating tumor cells (CTC) that could be used in place of the more invasive and potentially risky methods of tissue biopsy.
- Conditions
- Chaperonin-Containing TCP-1, Circulating Tumor Cells, CCT, CTC
- Trial name
- NCT06068348
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
HNSCC
WGA in Platinum-refractory HNSCC Underwent Nivolumab
To choose a subgroup who could clearly benefit from Nivolumab, we are proposing a prospective observational study. Whole-genome study (WGS) analysis will be performed on archived cancer tissues from patients who were (1)…
- Trial name
- NCT03917537
- Testing
- HNSCC patients have used Nivolumab
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Breast Abnormality
Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma
With an estimated > 2 million women with undetected breast cancer in the United States, the need for improved early detection is imperative.
- Trial name
- NCT01322750
- Where
- United States
- Volunteers
- 3,125 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Medical Center
Non Small Cell Lung Cancer, Chronic Obstructive Pulmonary Disease
Study of Use of CTC in NSCLC
The purpose of this study is to assess whether the detection of circulating tumor cells (CTC) could be used as a tool to earlier diagnose, more accurately predict treatment response / failure and predict overall survival in…
- Trial name
- NCT01990651
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Cancer Stem Cells, Postoperative Recurrence and Metastasis
Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology
The aim of this study is to establish a platform of detecting and sorting circulating tumor stem cells from peripheral blood in HCC patients; to investigate the relationship between circulating tumor stem cells and their effects…
- Conditions
- Cancer Stem Cells, Postoperative Recurrence and Metastasis, Hepatocellular Carcinoma
- Trial name
- NCT02727673
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
HER2-positive Metastatic Breast Cancer, Ovarian Cancer
Feasibility of a New Technology for Isolating Circulating Tumour Cells
This is a prospective interventional single-site research with a collection of biological samples. The primary objective of the trial is to assess the ability of the "new technology" to isolating circulating tumor cells (CTC) in…
- Conditions
- HER2-positive Metastatic Breast Cancer, Ovarian Cancer, Hormone-resistant Prostate Cancer, Circulating Tumor Cell
- Trial name
- CTC-SMMiL-E (NCT03979339)
- Testing
- Blood sample collection
- Where
- France
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Centre Oscar Lambret
Non-small Cell Lung Cancer
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported.
- Trial name
- FOCUS-C (NCT05334277)
- Testing
- Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
- Where
- 26 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Oral Cancer
Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment.
- Trial name
- NCT07296250
- Testing
- low-dose oral chemotherapy
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Thoracic Cancer, Ovarian Cancer
Project CADENCE (CAncer Detected Early caN be CurEd)
With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be…
- Conditions
- Thoracic Cancer, Ovarian Cancer, Liver Cancer, Prostate Cancer
- Trial name
- CADENCE (NCT05633342)
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- MiRXES Pte Ltd
Circulating Tumor Cells
Cancer DNA Screening Pilot Study (CANDACE)
The investigators have developed an assay that can sensitively and specifically detect DNA mutations circulating in human plasma that may be indicators of the presence of a solid tumor.
- Trial name
- CANDACE (NCT02808884)
- Testing
- Circulating tumor DNA assay
- Where
- Canada
- Volunteers
- 1,514 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Lung Cancer, Lung Cancer, Nonsmall Cell
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
A central challenge in the fight against lung cancers is how to detect disease in a noninvasive manner before it is detectable by imaging methods.
- Conditions
- Lung Cancer, Lung Cancer, Nonsmall Cell, Lung Cancer, Small Cell
- Trial name
- NCT03499678
- Where
- Kazakhstan
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- HKGepitherapeutics
Neoplastic Cells, Circulating
The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in renal cancer could play an important role in…
- Trial name
- NCT02450448
- Testing
- Flow cytometry (FCM), RT-PCR
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Breast Cancer
Circulating Tumour Cells Characterization in Breast Cancer Patients
In the current scenario, a reliable liquid biopsy method for predicting outcomes in solid tumors, especially among breast cancer patients, is lacking.
- Trial name
- BioCellPhe (NCT06048835)
- Testing
- Blood sample
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Early Detection of Cancer, Cancer
PATHFINDER 2: A Multi-Cancer Early Detection Study
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America.
- Trial name
- NCT05155605
- Testing
- Multi-Cancer Early Detection Test
- Where
- 56 sites in United States, Canada
- Volunteers
- 35,883 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Breast Cancer
Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics
Utilization of circulating-tumor-cell (CTC) and cell free DNA (cfDNA) as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest.
- Trial name
- NCT03511859
- Where
- Taiwan
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- CellMaxLife